Pharmaceuticals

Global Prostate Cancer Drugs Market 2026 expected to reach $26.15 billion by 2030

March 24, 2026 by Marketing Posting

The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.

What Will Be The Estimated Market Valuation Of The Prostate Cancer Drugs Market By The End Of 2030?

The prostate cancer drugs market has experienced robust growth in recent years. It is anticipated to increase from $19.51 billion in 2025 to $20.54 billion in 2026, demonstrating a compound annual growth rate (CAGR) of 5.3%. Historically, this expansion has been driven by factors such as an aging male population, increased prostate cancer screening, widespread adoption of hormone therapy, the expansion of oncology clinics, and rising cancer awareness.

The prostate cancer drugs market size is projected to experience substantial expansion over the coming years, reaching $26.15 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 6.2%. This growth during the forecast period is driven by factors such as the rise in targeted and immunotherapy drugs, an increasing prevalence of advanced prostate cancer, a greater emphasis on treatment personalization, broader healthcare access, and an increase in oncology spending. Key developments anticipated within this period involve a surge in hormonal therapy for early treatment, enhanced adoption of targeted prostate cancer drugs, a heightened focus on castration-resistant prostate cancer, an expansion of combination therapy methods, and an increase in hospital-based prostate cancer care.

Download the Free Sample Report to Explore Key Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=2592&type=smp

Which Market Drivers Are Supporting The Expansion Of The Prostate Cancer Drugs Market?

The increasing men geriatric population is expected to propel the growth of the prostate cancer drugs market going forward. This segment of the male demographic, encompassing individuals aged 65 and older, typically experiences a greater prevalence of age-related health conditions that demand specialized medical attention. This rise in the aging male population stems from improved healthcare access, declining mortality rates, and extended lifespans globally. The growing geriatric male population bolsters the prostate cancer drugs sector by expanding the number of patients who need hormonal therapies, immunotherapies, chemotherapy, and targeted medicines for effective disease management and improved survival. For instance, in February 2025, as per the World Health Organization, a Switzerland-based international public health organization, global life expectancy at birth reached 73.3 years in 2024, and the worldwide population aged 60 and older is projected to increase from 1.1 billion in 2023 to 1.4 billion by 2030. Consequently, the increasing men geriatric population is a key driver for the growth of the prostate cancer market.

Which Segment Classifications Shape The Prostate Cancer Drugs Market?

The prostate cancer drugs market covered in this report is segmented –

1) By Type: Hormone Sensitive Prostate Cancer, Hormone Refractory Prostate Cancer

2) By Therapy: Hormonal Therapy, Chemotherapy, Immunotherapy, Targeted Therapy

3) By End User: Hospitals, Clinics, Other End-Users

Subsegments:

1) By Hormone Sensitive Prostate Cancer: Early-Stage Prostate Cancer, Locally Advanced Prostate Cancer, Metastatic Prostate Cancer

2) By Hormone Refractory Prostate Cancer: Castration-Resistant Prostate Cancer (CRPC), Metastatic Castration-Resistant Prostate Cancer (mCRPC)

How Are Trends Impacting The Prostate Cancer Drugs Market?

Leading firms within the prostate cancer drugs market collaborate on bringing innovative products to market and securing their approval from federal bodies to increase their earnings. The creation and subsequent approval of pharmaceuticals constitute a time-consuming and intricate procedure, making it crucial for pharmaceutical developers to comprehend the governing regulations and commercialization routes required to guarantee adequate safety and efficacy. An example of this is the announcement in June 2023 by AstraZeneca PLC, a UK-based pharmaceutical company, and Merck & Co. Inc., a US-based pharmaceutical company, revealing that the United States Food and Drug Administration (USFDA), a US-based federal agency of the Department of Health and Human Services, had granted approval for LYNPARZA (olaparib) Plus Abiraterone and Prednisone or Prednisolone for Treatment of Adult Patients With BRCA-Mutated Metastatic Castration-Resistant Prostate Cancer (mCRPC). This approval was underpinned by the finding that LYNPARZAplus abi/pred showed notable clinical benefits in both radiographic progression-free survival (rPFS) and overall survival (OS) when contrasted with abi/pred only in patients with BRCAm mCRPC, as per an exploratory subgroup analysis from the Phase 3 PROpel trial.

Which Companies Are Expanding Their Footprint In The Prostate Cancer Drugs Market?

Major companies operating in the prostate cancer drugs market are Astellas Pharma Inc., AstraZeneca PLC, Johnson & Johnson, Sanofi S.A., Bayer AG, Abbott Laboratories, Pfizer Inc., Novartis International AG, F. Hoffmann-La Roche Ltd., Tolmar Inc., AbbVie Inc., Siemens Healthineers AG, Genomic Health Inc., OPKO Health Inc., Siemens Healthcare GmbH, MDxHealth SA, Myriad Genetics Inc., Janssen Biotech Inc., Clovis Oncology Inc., Merck Sharp & Dohme Corp., Dendreon Corporation, Ferring Pharmaceuticals Inc., Ipsen Biopharmaceuticals Inc., Merck & Co. Inc., Eli Lilly and Company Inc., Bristol-Myers Squibb Company, Takeda Pharmaceutical Company Limited, Novartis AG, Amgen Inc., Regeneron Pharmaceuticals Inc., Exelixis Inc.

Read the full prostate cancer drugs market report here:

https://www.thebusinessresearchcompany.com/report/prostate-cancer-drugs-global-market-report

How Is The Prostate Cancer Drugs Market Distributed Across Key Geographic Regions?

North America was the largest region in the prostate cancer drugs market in 2025. Middle East is expected to be the fastest-growing region in the prostate cancer drugs market during the forecast period. The regions covered in the prostate cancer drugs market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Tailored Prostate Cancer Drugs Market Research Report For Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=2592&type=smp

Browse Through More Reports Similar to the Global Prostate Cancer Drugs Market 2026, By The Business Research Company

Prostate Cancer Drugs Market Report 2026

https://www.thebusinessresearchcompany.com/report/prostate-cancer-drugs-global-market-report

Metastatic Cancer Drugs Market Report 2026

https://www.thebusinessresearchcompany.com/report/metastatic-cancer-drugs-global-market-report

Bladder Cancer Drugs Market Report 2026

https://www.thebusinessresearchcompany.com/report/bladder-cancer-drugs-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795